B010-A

N/A

Report date: 2022/10/27 20:00:45

Base Information

Drug NameB010-A
Drug Alias NameAnti-GPC3 CAR-T cell therapy (Shanghai Pharmaceuticals)B010-A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTongji UniversityShanghai Pharmaceuticals Holding Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A